Protalix BioTherapeutics (PLX) Debt Ratio (2011 - 2024)

Protalix BioTherapeutics' (PLX) quarterly Debt Ratio came in at 0.22 in Q2 2024, down 1.87% quarter-over-quarter from 0.23 in Q1 2024.

Protalix BioTherapeutics (PLX) Debt Ratio (2011 - 2024) Analysis & Trends

Protalix BioTherapeutics' Debt Ratio history runs 11 years deep, the most recent figure standing at 0.22 for Q2 2024.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.22 in Q2 2024; TTM through Jun 2024 was 0.22, a N/A change from a year earlier, with the FY2023 full-year figure at 0.24, changed N/A from the prior year.
Debt Ratio declined to 0.22 in Q2 2024 per PLX's latest filing, from 0.23 in the prior quarter.
Across five years, Debt Ratio topped out at 0.8 in Q4 2020 and bottomed at 0.04 in Q3 2021.
The 4-year median for Debt Ratio is 0.24 (2023), against an average of 0.35.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Protalix BioTherapeutics	190.95 Mn	180.16 Mn	29.62 Mn	-

Download Data